been digging into some marijuana stocks under $10 and found a few that analysts are actually bullish on right now. the sector's been getting some unexpected political tailwinds lately, which is interesting to watch.



organigram (ogi) caught my eye first - canadian company, market cap around $192m. they actually turned profitable last quarter which is wild for cannabis operators. revenue hit $30m, beat expectations, and they're targeting like $10m in cost cuts for the year. they're also making moves into germany which could be a big play. analysts see this going to like $2.95 which would be solid upside from here. definitely one of the best marijuana stocks under $10 if you're looking at fundamentals.

verano (vrnof) is bigger at like $1.1b market cap but got hit hard this year, down 28% ytd. they're trading cheap right now at 1.25 p/s though. the florida expansion is interesting - they've got 152 dispensaries nationwide now and pushing for adult-use legalization there. analysts are pretty confident, consensus strong buy with $8.50 target. that's like 160% upside which seems optimistic but worth monitoring.

cresco labs (crlbf) is another chicago-based player, $810m market cap. they had a rough quarter but their operational margins are actually impressive - 52% adjusted gross profit. the sunnyside dispensaries are holding strong market share in key states. trading at 0.78 p/s which is 70% below their 5-year average, so valuation looks beaten down. analysts still rating it strong buy with $3.48 target.

the thing about these best marijuana stocks under $10 is they're all pretty volatile and policy-dependent. if federal regulations shift favorably, could be interesting. if not, you're holding bags. personally i think the risk/reward is there if you can stomach the swings and hold long term. not financial advice but worth keeping on your radar if you're into the sector.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments